Rapidity of treatment response and outcome in type 1 autoimmune hepatitis

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 161-167

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Corticosteroid therapy; Progression to cirrhosis; Response rate

Indexed keywords

AZATHIOPRINE; HLA DR ANTIGEN; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 67349145925     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.02.026     Document Type: Article

References (30)

1. Soloway R.D., Summerskill W.H.J., Baggenstoss A.H., Geall M.G., Gitnick G.L., Elveback L.R., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63 (1972) 820-833
2. Floreani A., Niro G., Rosa Rizzotto E., Antoniazzi S., Ferrara F., Carderi I., et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 24 (2006) 1051-1057
3. Seo S., Toutounjian R., Conrad A., Blatt L., and Tong M.J. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 23 (2008) 1410-1414
4. Czaja A.J., and Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40 (2004) 644-650
5. Czaja A.J., Davis G.L., Ludwig J., and Taswell H.F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4 (1984) 622-627
6. Verma S., Gunuwan B., Mendler M., Govindrajan S., and Redeker A. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission, and plasma cell activity in the liver biopsy. Am J Gastroenterol 99 (2004) 1510-1516
7. Miyake Y., Iwasaki Y., Terada R., Takagi S., Okamaoto R., Ikeda H., et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43 (2005) 951-957
8. Montano-Loza A., Carpenter H.A., and Czaja A.J. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 102 (2007) 1005-1012
9. Czaja A.J., Beaver S.J., and Shiels M.T. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 92 (1987) 215-219
10. Czaja A.J., Menon K.V.N., and Carpenter H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35 (2002) 890-897
11. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. J Hepatol 43 (2005) 425-433
12. Montano-Loza A., Carpenter H.A., and Czaja A.J. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 27 (2007) 507-515
13. Kanzler S., Gerken G., Lohr H., Galle P.R., Meyer zum Buschenfelde K.H., and Lohse A.W. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 34 (2001) 354-355
14. Johnson P.J., McFarlane I.G., and Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 (1995) 958-963
15. Czaja A.J. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11 (1990) 1044-1049
16. Czaja A.J., and Carpenter H.A. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39 (2004) 1631-1638
17. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
18. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
19. Czaja A.J., and Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002) 479-497
20. Czaja A.J., and Manns M.P. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 90 (1995) 1206-1211
21. Czaja A.J., and Carpenter H.A. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105 (1993) 1824-1832
22. Soloway R.D., Baggenstoss A.H., Schoenfield L.J., and Summerskill W.H.J. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 20 (1975) 1087-1090
23. Montano Loza A., and Czaja A.J. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 202-214
24. Summerskill W.H.J., Korman M.G., Ammon H.V., and Baggenstoss A.H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16 (1975) 876-883
25. Czaja A.J., Wolf A.M., and Baggenstoss A.H. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80 (1981) 687-692
26. Montano-Loza A., Carpenter H.A., and Czaja A.J. Clinical significance of HLA DRB1*03-DRB1*04 in type 1 autoimmune hepatitis. Liver Int 26 (2006) 1201-1208
27. Czaja A.J., and Carpenter H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43 (2006) 532-538
28. Villanueva J.L., Solana R., Alonso M.C., and Pena J. Changes in the expression of HLA class II antigens on peripheral blood monocytes from aged humans. Dis Markers 8 (1990) 85-91
29. Murasko D.M., and Goonewardene I.M. T cell function in aging: mechanisms of decline. Ann Rev Gerontol Geriatr 10 (1990) 71-96
30. Kanzler S., Lohr H., Gerken G., Galle P.R., and Lohse A.W. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 39 (2001) 339-341